{
    "clinical_study": {
        "@rank": "146565", 
        "brief_summary": {
            "textblock": "This study will examine whether the new investigational drug EPO906, given by intravenous\n      infusion (IV directly into the vein), is effective in shrinking tumors and preventing the\n      growth of cells that cause colorectal  cancer."
        }, 
        "brief_title": "EPO906 Therapy in Patients With Advanced Colorectal Cancer", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Colonic Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colonic Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must meet the following criteria to be eligible for the study:\n\n          -  Histologically or cytologically documented evidence of colorectal cancer with at\n             least one measurable lesion (if previous radiation treatment, the target lesion must\n             have demonstrated progression since the radiation)\n\n          -  The patient should have failed or progressed on no more than two prior chemotherapies\n             for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine\n             and either Irinotecan or oxaliplatin, or any combination of these agents, with the\n             last chemotherapy having contained Irinotecan or oxaliplatin)\n\n          -  Patients who have received only adjuvant therapy for their disease are eligible, as\n             long as they have relapsed within six months of completing such therapy and that\n             therapy contained 5-FU and Irinotecan or oxaliplatin administered in combination as\n             part of an investigational protocol\n\n          -  Must have a life expectancy of greater than three (3) months.\n\n        Exclusion Criteria\n\n        The following patients are not eligible for the study:\n\n          -  Patients with symptomatic CNS metastases or leptomeningeal involvement\n\n          -  Patients with unresolved bowel obstruction\n\n          -  Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\n\n          -  Patients with severe cardiac insufficiency\n\n          -  Patients who have undergone major surgery for any cause less than 4 weeks prior to\n             study entry\n\n          -  Patients with radiation therapy or chemotherapy within the last four weeks\n\n          -  Patients taking Coumadin or other warfarin-containing agents with the exception of\n             low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports\n\n          -  History of another malignancy within 5 years prior to study entry except curatively\n             treated non-melanoma skin cancer or cervical cancer in situ\n\n          -  Patients with active or suspected acute or chronic uncontrolled infection including\n             abcesses or fistulae\n\n          -  HIV+ patients\n\n          -  Pregnant or lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035087", 
            "org_study_id": "CEPO906A2201"
        }, 
        "intervention": {
            "intervention_name": "epothilone b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epothilone B", 
                "Epothilones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "colon", 
            "rectum", 
            "colorectal", 
            "rectal", 
            "cancer", 
            "tumor", 
            "tumour", 
            "neoplasm", 
            "carcinoma", 
            "intravenous", 
            "epothilone"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Brunswick", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08901"
                }, 
                "name": "Cancer Institute of New Jersey (CINJ)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035087"
        }, 
        "responsible_party": {
            "name_title": "External Affairs", 
            "organization": "Novartis  Pharmaceuticals"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to progression"
            }, 
            {
                "measure": "Overall survival"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "Cancer Institute of New Jersey (CINJ)": "40.486 -74.452"
    }
}